Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...
Sorry, currently no updates on this topic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback